P538 Duration of remission with exclusive enteral nutrition in Crohn's disease

contrary only 36% of patients still active after induction were able to reach clinical remission at twelve months (p = 0.009, OR = 6.96). After twelve months 58.3% of patients were in remission according to HBI. 61% of patients achieving LF normalization at the end of induction were in clinical remission at one year (p = 0.004, OR = 0.06), while only 39% of patients with abnormal LF (p = 0.004, OR = 15.45). 95% patients with normal CRP after induction were in clinical remission at one year (p = 0.003, OR = 0.06), while only 4.5% of those showing abnormal CRP (p = 0.003, OR = 15.75). Linear regression models found that clinical remission combined with early CRP and LF normalization after induction is the best predictor of maintenance of clinical remission at one year. Conclusions: Clinical activity and biochemical markers performed at the end of induction proved to be reliable in predicting the course of CD in the long term maintenance treatment with adalimumab, therefore clinical and laboratory monitoring should be performed routinely in these patients.